共 50 条
A Worthy Finding: Decrease in Total Cholesterol and Low-Density Lipoprotein Cholesterol in Treated Mild Subclinical Hypothyroidism
被引:34
|作者:
Zhao, Meng
[1
,3
,4
]
Liu, Lu
[1
,3
,4
]
Wang, Fei
[5
]
Yuan, Zhongshang
[6
]
Zhang, Xu
[1
,3
,4
]
Xu, Chao
[1
,3
,4
]
Song, Yongfeng
[1
,3
,4
]
Guan, Qingbo
[1
,3
,4
]
Gao, Ling
[2
,3
,4
]
Shan, Zhongyan
[7
]
Zhang, Haiqing
[1
,3
,4
]
Zhao, Jiajun
[1
,3
,4
]
机构:
[1] Shandong Univ, Shandong Prov Hosp, Dept Endocrinol, Jinan 250021, Shandong, Peoples R China
[2] Shandong Univ, Shandong Prov Hosp, Ctr Sci, Jinan 250021, Shandong, Peoples R China
[3] Shandong Clin Med Ctr Endocrinol & Metab, Jinan, Peoples R China
[4] Shandong Acad Clin Med, Inst Endocrinol & Metab, Jinan, Peoples R China
[5] Ningxia Med Univ, Sch Clin Med, Yinchuan, Peoples R China
[6] Shandong Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Jinan 250021, Shandong, Peoples R China
[7] China Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Shenyang, Peoples R China
来源:
关键词:
CORONARY-HEART-DISEASE;
THYROID-STIMULATING HORMONE;
INTIMA-MEDIA THICKNESS;
SERUM-LIPID PROFILES;
ALL-CAUSE MORTALITY;
L-THYROXINE;
HASHIMOTOS-THYROIDITIS;
ENDOTHELIAL FUNCTION;
CARDIOVASCULAR RISK;
CONTROLLED-TRIAL;
D O I:
10.1089/thy.2016.0010
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Background: Mild subclinical hypothyroidism (SCH) affects a large number of people and is known to be a risk factor for dyslipidemia. However, whether mild SCH patients should be treated with L-thyroxine to improve lipid profiles remains controversial. In addition, it is also unclear whether all mild SCH patients can benefit from L-thyroxine treatment, regardless of basal thyrotropin or lipid levels. This study aimed to assess the effects of L-thyroxine replacement therapy on the lipid profiles of mild SCH patients. Methods: This open-label randomized controlled trial was performed in Ningyang County, Shandong Province, China. A total of 378 mild SCH patients with diagnoses confirmed by two thyroid function tests were randomly assigned to either the intervention group (L-thyroxine replacement therapy) or the control group (no treatment). The primary outcome was a change in serum total cholesterol (TC) concentration. Results: In all, 369 participants completed the 15-month follow-up period. Reduced TC concentrations were more prominent in the intervention group than they were in the control group (-0.41mmol/L vs. -0.17 mmol/L; p = 0.012), and changes in low-density lipoprotein cholesterol levels exhibited the same trend. Subgroup analyses were performed to assess the effects of L-thyroxine in patients with different thyrotropin or TC levels. When the study population was stratified according to basal thyrotropin concentration, all patients who had received L-thyroxine showed reduced TC levels (p < 0.001). The treatment was similarly beneficial for all patients, regardless of basal TC level. Even for subjects with TC levels <5.18 mmol/L, serum TC concentrations remained unchanged in the intervention group (p = 0.936) but increased by 0.35 mmol/L in the control group (p = 0.004). Conclusions: The findings suggest that mild SCH patients could benefit from L-thyroxine treatment to improve lipid profiles, regardless of basal thyrotropin or TC concentrations.
引用
收藏
页码:1019 / 1029
页数:11
相关论文